Study Finds ApoB Testing More Effective Than LDL for Guiding Lipid Therapy

Routine blood tests that measure low-density lipoprotein (LDL), commonly known as “bad” cholesterol, are widely used to guide lipid-lowering therapy, but they do not always provide a complete picture of cardiovascular risk. This limitation persists even as heart disease remains the leading cause of death in the United States. New findings indicate that apolipoprotein B (apoB) testing may offer a more accurate and cost-effective way to guide therapy than LDL or non–high-density lipoprotein (non-HDL) cholesterol alone.

Northwestern Medicine (Chicago, IL, USA) researchers evaluated apolipoprotein B (apoB) testing as an alternative to LDL and non‑HDL cholesterol for directing cholesterol‑lowering therapy, with findings published in JAMA on April 8, 2026. ApoB is a blood test that counts the total number of harmful particles in circulation, providing a more complete assessment of risk than concentration‑based cholesterol measures. Despite supportive evidence, apoB is not widely used because it typically requires an additional blood test beyond the standard cholesterol panel, affecting cost and convenience in routine care.

The team used a large computer simulation model representing 250,000 U.S. adults who were eligible for statins and had no existing cardiovascular disease. Three goal‑directed strategies were compared: targeting LDL cholesterol to less than 100 mg/dL, non‑HDL cholesterol to less than 118 mg/dL, or apoB to less than 78.7 mg/dL. If patients did not meet their assigned goal, treatment was intensified with stronger statins and then by adding ezetimibe. The model tracked lifetime outcomes including heart attacks, strokes, life expectancy, quality of life, and healthcare costs.

ApoB‑guided care outperformed LDL‑ and non‑HDL–guided strategies, improving population health and saving more lives at a cost considered good value for U.S. healthcare payers. The study notes that an expanding therapeutic arsenal for lipid management, along with new guidelines from the American Heart Association and 10 other medical associations recommending earlier initiation of therapy for many patients, makes precise risk targeting increasingly important.

“We found that apoB testing to intensify cholesterol-lowering medication would prevent more heart attacks and strokes than current practice, and that these health benefits were achieved at a cost that represents good value for U.S. healthcare payers,” said Ciaran Kohli‑Lynch, assistant professor of preventive medicine in the division of epidemiology at Northwestern University Feinberg School of Medicine.

Related Links
Northwestern Medicine
Northwestern University Feinberg School of Medicine